TSH Biopharm (ROCO:8432) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
91 GF Score
Price NT$50.60
GF Value NT$68.62
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is TSH Biopharm Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:8432
91GF Score
TSH Biopharm Corp Ltd ROCO:8432
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.60 is trading 26.3% below its estimated GF Value™ of NT$68.62. GuruFocus considers TSH Biopharm to be Modestly Undervalued.

Key valuation signals for ROCO:8432:

  • Cash Payments:
  • GF Value™: NT$68.62 vs. price of NT$50.60 (26.3% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
91GF Score

Get the complete analysis for ROCO:8432

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.60
Price
NT$68.62
GF Value